BioCentury | Dec 4, 2020
Deals
Artios deal fourth for synthetic lethality in 2020: Data Byte
...well as double-digit option fees, $860 million in milestones per target, and double-digit royalties. In August, Impact Therapeutics Inc. ...
...syndrome RecQ like helicase Karen Tkach Tuzman Artios Pharma Ltd. Merck KGaA Repare Therapeutics Inc. GlaxoSmithKline plc Ideaya Biosciences Inc. Bristol-Myers Squibb Co. Impact Therapeutics Inc. Shanghai...
...syndrome RecQ like helicase Karen Tkach Tuzman Artios Pharma Ltd. Merck KGaA Repare Therapeutics Inc. GlaxoSmithKline plc Ideaya Biosciences Inc. Bristol-Myers Squibb Co. Impact Therapeutics Inc. Shanghai...